scholarly journals Frequency of Voriconazole ResistanceIn Vitroamong Spanish Clinical Isolates ofCandidaspp. According to Breakpoints Established by the Antifungal Subcommittee of the European Committee on Antimicrobial Susceptibility Testing

2011 ◽  
Vol 55 (4) ◽  
pp. 1794-1797 ◽  
Author(s):  
M. Cuenca-Estrella ◽  
A. Gomez-Lopez ◽  
I. Cuesta ◽  
O. Zaragoza ◽  
E. Mellado ◽  
...  
Keyword(s):  
Candida Albicans ◽  
Antimicrobial Susceptibility ◽  
Candida Glabrata ◽  
Susceptibility Testing ◽  
Antimicrobial Susceptibility Testing ◽  
Clinical Isolates ◽  
Significant Percentage ◽  
European Committee ◽  
Resistant Strains ◽  
High Mics

ABSTRACTA total of 4,226 Spanish clinical isolates ofCandidaspp. were analyzed to assess resistance to voriconazole according to breakpoints established by the European Committee for Antimicrobial Susceptibility Testing (where susceptibility [S] to voriconazole corresponds to a MIC of ≤0.12 mg/liter). Resistance was uncommon amongCandida albicans(5%),C. parapsilosis(1.2%), andC. tropicalis(11%) isolates. Voriconazole MICs of >0.12 mg/liter were more frequent amongCandida glabrataandC. kruseiisolates. A significant percentage of voriconazole-resistant strains came from oropharyngeal infections and exhibited high MICs of other azoles.

scholarly journals Fenticonazole Activity Measured by the Methods of the European Committee on Antimicrobial Susceptibility Testing and CLSI against 260 Candida Vulvovaginitis Isolates from Two European Regions and Annotations on the Prevalent Genotypes

2009 ◽  
Vol 53 (5) ◽  
pp. 2181-2184 ◽  
Author(s):  
Stavroula Antonopoulou ◽  
Michel Aoun ◽  
Evangelos C. Alexopoulos ◽  
Stavroula Baka ◽  
Emanuel Logothetis ◽  
...  
Keyword(s):  
Antimicrobial Susceptibility ◽  
Candida Glabrata ◽  
Susceptibility Testing ◽  
Antimicrobial Susceptibility Testing ◽  
European Regions ◽  
Fluconazole Resistance ◽  
European Committee ◽  
Interclass Correlation Coefficient ◽  
Interclass Correlation ◽  
First Time

ABSTRACT The activity of fenticonazole was studied against 260 West and Southeast European vulvovaginal candidiasis isolates, and low MICs were displayed. Fenticonazole was assessed by European Committee on Antimicrobial Susceptibility Testing and CLSI microdilution methods for the first time, and the results showed excellent agreement (97%) and significant interclass correlation coefficient (P < 0.0001). Also, the levels of agreement for the results for itraconazole, fluconazole, and ketoconazole were 84%, 90%, and 98% (P < 0.0001), respectively. Multilocus typing by PCR fingerprinting and subsequent cluster analysis delineated geographically associated alignments for Candida albicans and fluconazole resistance-related clusters for Candida glabrata.

scholarly journals Comparative In Vitro Activities of Caspofungin and Micafungin, Determined Using the Method of the European Committee on Antimicrobial Susceptibility Testing, against Yeast Isolates Obtained in France in 2005-2006

2007 ◽  
Vol 52 (2) ◽  
pp. 778-781 ◽  
Author(s):  
E. Dannaoui ◽  
O. Lortholary ◽  
D. Raoux ◽  
M. E. Bougnoux ◽  
G. Galeazzi ◽  
...  
Keyword(s):  
Candida Albicans ◽  
Antimicrobial Susceptibility ◽  
Candida Glabrata ◽  
Candida Parapsilosis ◽  
Susceptibility Testing ◽  
Candida Guilliermondii ◽  
Candida Krusei ◽  
Clear Correlation ◽  
European Committee

ABSTRACT The in vitro activities of caspofungin and micafungin against 1,038 yeast isolates have been determined. The caspofungin and micafungin MICs were lower for Candida albicans, Candida glabrata, and Candida tropicalis than for Candida parapsilosis, Candida guilliermondii, and Candida krusei. A clear correlation was seen between the MICs for the two drugs.

scholarly journals CIM City: the Game Continues for a Better Carbapenemase Test

2019 ◽  
Vol 57 (7) ◽  
Author(s):  
Romney M. Humphries
Keyword(s):  
Antimicrobial Susceptibility ◽  
Clinical Microbiology ◽  
Susceptibility Testing ◽  
Clinical Care ◽  
Antimicrobial Susceptibility Testing ◽  
European Committee ◽  
Link Type ◽  
Clinical Laboratories ◽  
The Right

ABSTRACT The Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing agree that carbapenemase testing is not necessary for clinical care, provided that the laboratory is up to date with current breakpoints. Nonetheless, publication on the development and modification of carbapenemase tests continues, as is the case in this issue of the Journal of Clinical Microbiology (R. W. Beresford and M. Maley, J Clin Microbiol 57:e01852-18, 2019, https://doi.org/10.1128/JCM.01852-18). This commentary explores modifications to the carbapenem inactivation method—but is this the right focus for clinical laboratories?

scholarly journals Point-Counterpoint: Differences between the European Committee on Antimicrobial Susceptibility Testing and Clinical and Laboratory Standards Institute Recommendations for Reporting Antimicrobial Susceptibility Results

2019 ◽  
Vol 57 (9) ◽  
Author(s):  
Gunnar Kahlmeter ◽  
Christian G. Giske ◽  
Thomas J. Kirn ◽  
Susan E. Sharp
Keyword(s):  
Antimicrobial Susceptibility ◽  
Susceptibility Testing ◽  
Antimicrobial Susceptibility Testing ◽  
Test Results ◽  
Diffusion Test ◽  
Disk Diffusion Test ◽  
Technical Variability ◽  
European Committee ◽  
Clinical Laboratories ◽  
Antibiotic Susceptibility Test

INTRODUCTION Antibiotic susceptibility test results are among the most important results issued by clinical microbiology laboratories because they routinely guide critical treatment decisions. Interpretations of MIC or disk diffusion test results, such as “susceptible” or “resistant,” are easily understood. Clinical laboratories also need to determine whether and how their reports will reflect more complex situations. Such situations include, first, whether there is need to administer higher or more frequent doses of antibiotic than usual for clinical efficacy; second, whether an antimicrobial is likely to be effective at a body site where it concentrates; and third, whether there is some uncertainty in the test results due to technical variability that cannot be eliminated. Two leading organizations that set standards for antimicrobial susceptibility testing, the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI), have taken different strategies to deal with these challenges. In this Point-Counterpoint, Gunnar Kahlmeter and Christian Giske discuss how EUCAST is addressing these issues, and Thomas Kirn and Susan Sharp discuss the CLSI approach.

scholarly journals Mutations in the fks1 Gene in Candida albicans, C. tropicalis, and C. krusei Correlate with Elevated Caspofungin MICs Uncovered in AM3 Medium Using the Method of the European Committee on Antibiotic Susceptibility Testing

2008 ◽  
Vol 52 (9) ◽  
pp. 3092-3098 ◽  
Author(s):  
Marie Desnos-Ollivier ◽  
Stéphane Bretagne ◽  
Dorothée Raoux ◽  
Damien Hoinard ◽  
Françoise Dromer ◽  
...  
Keyword(s):  
Candida Albicans ◽  
Antibiotic Susceptibility ◽  
Susceptibility Testing ◽  
Antifungal Susceptibility ◽  
Clinical Isolates ◽  
Antibiotic Susceptibility Testing ◽  
Wild Type ◽  
European Committee ◽  
Rpmi Medium

ABSTRACT Mutations in two specific regions of the Fks1 subunit of 1,3-β-d-glucan synthase are known to confer decreased caspofungin susceptibility on Candida spp. Clinical isolates of Candida spp. (404 Candida albicans, 62 C. tropicalis, and 21 C. krusei isolates) sent to the French National Reference Center were prospectively screened for susceptibility to caspofungin in vitro by the broth microdilution reference method of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing (AFST-EUCAST). Twenty-eight isolates (25 C. albicans, 2 C. tropicalis, and 1 C. krusei isolate) for which the caspofungin MIC was above the MIC that inhibited 90% of the isolates of the corresponding species (MIC90) were subjected to molecular analysis in order to identify mutations in the fks1 gene. Substitutions in the deduced protein sequence of Fks1 were found for 8 isolates, and 20 isolates had the wild-type sequence. Among the six C. albicans isolates harboring mutations, six patterns were observed involving amino acid changes at positions 641, 645, 649, and 1358. For C. tropicalis, one isolate showed an L644W mutation, and for one C. krusei isolate, two mutations, L658W and L701M, were found. Two media, RPMI medium and AM3, were tested for their abilities to distinguish between isolates with wild-type Fks1 and those with mutant Fks1. In RPMI medium, caspofungin MICs ranged from 0.25 to 2 μg/ml for wild-type isolates and from 1 to 8 μg/ml for mutant isolates. A sharper difference was observed in AM3: all wild-type isolates were inhibited by 0.25 μg/ml of caspofungin, while caspofungin MICs for all mutant isolates were ≥0.5 μg/ml. These data demonstrate that clinical isolates of C. albicans, C. tropicalis, and C. krusei with decreased susceptibility to caspofungin in vitro have diverse mutations in the fks1 gene and that AM3 is potentially a better medium than RPMI for distinguishing between mutant and wild-type isolates using the AFST-EUCAST method.

Sign in / Sign up

Export Citation Format

Share Document